OncLive TV

OncLive® TV is an editorial video program featuring one-on-one live and/or virtual interviews with key opinion leaders in the oncology field for their expert insight on breaking news, regulatory updates, practice-changing data presented at medical meetings, and other pivotal topics in a cancer specialty, including breast cancer, lung cancer, genitourinary cancers, gastrointestinal cancers, gynecologic cancers, and hematologic cancers.

Dr. Cutler on Treatment Options for Acute and Chronic GVHD

March 18th 2020

Corey S. Cutler, MD, MPH, FRCPC, discusses treatment options for patients with acute and chronic graft-versus-host disease.

Dr. Westin on the Role of R-CHOP in DLBCL

March 18th 2020

Jason Westin, MD, MS, FACP, discusses the role of rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone in diffuse large B-cell lymphoma.

Dr. Agarwal on the COSMIC-021 Trial Design in Castration-Resistant Prostate Cancer

March 17th 2020

Neeraj Agarwal, MD, discusses the design of cohort 6 in the phase Ib COSMIC-021 trial in metastatic castration-resistant prostate cancer.

Dr. Fendler on the Utility of 68Ga-PSMA-11 PET in Prostate Cancer

March 17th 2020

Wolfgang Fendler, MD, discusses the utility of 68Ga-PSMA-11 PET in prostate cancer.

Dr. Abdul-Hay on Treatment Considerations in ALL

March 17th 2020

Mohammad Maher Abdul-Hay, MD, an assistant professor in the Department of Medicine; director of the Clinical Leukemia Program in NYU Langone Health’s Perlmutter Cancer Center; and associate director for research in the Bellevue Cancer Center, discusses treatment considerations in acute lymphoblastic leukemia (ALL).

Dr. Hamid on the Progression of Therapy for Metastatic Prostate Cancer

March 17th 2020

Anis Hamid, MBBS, discusses the progression of therapy for metastatic prostate cancer.

Dr. Hamdan on Trial of Brentuximab Vedotin/Chemo in HIV-Associated Hodgkin Lymphoma

March 17th 2020

Ayad Hamdan, MD, hematologist and associate professor of medicine at Moores Cancer Center at the University of California, San Diego, discusses a pilot phase I/II trial with brentuximab vedotin (Adcetris) plus chemotherapy in patients with HIV-associated Hodgkin lymphoma.

Dr. Grossbard on the GALLIUM Study in Follicular Lymphoma

March 17th 2020

Michael L. Grossbard, MD, professor in the Department of Medicine, chief of the Hematology and Medical Oncology Inpatient Service at Tisch Hospital, and section chief of Hematology at NYU Langone Health’s Perlmutter Cancer Center, discusses the results of the phase III GALLIUM study in follicular lymphoma.

Dr. Mesa on the Utility of Fedratinib for Patients With Myelofibrosis Who Progress on Ruxolitinib

March 16th 2020

Ruben Mesa, MD, discusses the utility of fedratinib for patients with myelofibrosis who progress on first-line ruxolitinib.

Dr. Nagalla on the Challenges of Managing Thrombocytopenia in MPNs

March 16th 2020

Srikanth Nagalla, MD, discusses the challenges of managing thrombocytopenia in patients with myeloproliferative neoplasms.

Dr. Saint Fleur-Lominy on Differences Between Ruxolitinib and Fedratinib in MPNs

March 16th 2020

Shella Saint Fleur-Lominy, MD, PhD, discusses the differences between ruxolitinib and fedratinib in the treatment of patients with myeloproliferative neoplasms.

Dr. Ledermann on the Additive Effects of Olaparib and Bevacizumab in Ovarian Cancer

March 14th 2020

Jonathan A. Ledermann, BSc, MD, FRCP, discusses the additive effects of olaparib (Lynparza) and bevacizumab (Avastin) in advanced ovarian cancer.

Dr. Penson on Research With PARP Inhibitors in Ovarian Cancer

March 14th 2020

Richard T. Penson, MD, MRCP, discusses unexpected findings from the phase III SOLO3 trial and ongoing research with PARP inhibitors in ovarian cancer.

Dr. D'Cunha on Surgical Options for High-Risk Patients With Lung Cancer

March 14th 2020

Jonathan D'Cunha, MD, PhD, FACS, discusses surgical options for high-risk patients with lung cancer.

Dr. Cherington on the Use of Immunotherapy and Targeted Therapy in Lung Cancer

March 14th 2020

Chad Cherington, MD, discusses the use of immunotherapy and targeted therapy in lung cancer.

Dr. Katz on Eligibility Criteria for Up-front Surgery in Pancreatic Cancer

March 14th 2020

Matthew H.G. Katz, MD, FACS, discusses the eligibility criteria for up-front surgery in patients with pancreatic cancer.

Dr. Mesa on Challenges With JAK Inhibitors in Myelofibrosis

March 14th 2020

Ruben Mesa, MD, discusses the challenges with using JAK inhibitors in myelofibrosis.

Dr. Putcha on the Utility of Blood-Based Assays in CRC

March 14th 2020

Girish Putcha, MD, PhD, discusses the utility of blood-based assays in colorectal cancer.

Dr. Hershman on Misconceptions With the TAILORx Trial in HR+/HER2- Breast Cancer

March 13th 2020

Dawn L. Hershman, MD, MS, discusses the design of the phase III TAILORx trial in hormone receptor (HR)–positive, HER2-negative breast cancer.

Dr. Desai on Evolving Treatment Approaches in Lymphomas

March 13th 2020

Sameer Desai, MD, discusses current and emerging treatment options under evaluation in lymphomas.